Jonathan Silverberg has received honoraria as a consultant and/or advisory board member for AbbVie, Aldena, Aldena, Amgen, AObiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, Bodewell, Boehringer-Ingelheim, Bristell-Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Eli Lilly, FIDE, Galderma, GlaxoSmithKline, Incyte, Inmagene, Invea, Kiniksa, Leo Pharma, Merck, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, TARGET-RWE, Teva, Triveni, Union, UpToDate; speaker for AbbVie, Arcutis, Dermavant, Eli Lilly, Galderma, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; institution received grants from Galderma, Incyte, Pfizer. Valeria Aoki has served as an investigator in clinical trials (Sanofi, Amgen, Abbvie) and consultant/advisory board: Eli Lilly, Galderma, Abbvie. Yousef Binamer has received speaker honoraria for serving as a consultant for, and travel support from AbbVie, Eli Lilly, Janssen, Kyowa Kirin, NewBridge, Novartis, and Sanofi, and received research grants from Novartis and Sanofi. Brad Glick is an advisory board member, consultant, speaker and/or investigator for and received honoraria or grants from Amgen, AbbVie, AstraZeneca, Almirall, Acrutis, Bausch Health/Valeant, OrthoDermatologics, Boehringer Ingelheim, Bristol-Myers Squibb, Brickell Biotech, Cara Therapeutics, ChemoCentryx, Dermavant, Dermira, Eli Lilly, EPI/Novan Pharmaceuticals, Incyte, Janssen Pharmaceuticals, LEO Pharma, Galderma, Nimbus Lakshmi, Inc, Novartis Pharmaceutical Corporation, Sun Pharma, Pfizer, Sanofi, Regeneron, UCB Biopharmaceuticals and the CorEvitas AD, CorEvitas PSO and PROSE Registries. Dr. Glick is a shareholder of Top MD, LLC. Melinda Gooderham has been an investigator, speaker and/or advisor for: AbbVie, Acelyrin, Alumis, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Cara, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, JAMP Pharma, Janssen, LEO Pharma, L’Oreal, MedImmune, Meiji, Moonlake, Nektar, Nimbus, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tarsus, Takeda, UCB, Union, Ventyx and Vyne. Norito Katoh has received honoraria as a speaker/consultant for Sanofi, Maruho, Abbvie, Eli Lilly Japan, Taiho Pharmaceutical, Pfizer, Mitsubishi Tanabe Pharma, Jansen Pharma, Kyowa Kirin, Celgene Japan, Torii Pharmaceutical, and Otsuka Pharmaceutical, and has received grants as an investigator from Mitsubishi Tanabe Pharma, Torii Pharmaceutical, Maruho, Sun Pharma, Boehringer Ingelheim Japan, Eisai, and Leo Pharma. Andrew Pink has acted as investigator, speaker, advisor, received educational support from, or received research support from AbbVie, Lilly, Pfizer, Sanofi, Leo, Galderma, Amgen, Novartis, J&J, BMS, BI, UCB, Almirall and Celgene. Petra Staubach-Renz has served as a speaker or advisor for AbbVie, Almirall, BMS, Boehringer Ingelheim, Janssen, Infectopharm, Leo, Lilly, Novartis, Pfizer, Sanofi, Galderma, Pierre Fabre, Klinge Pharma, Beiersdorf, L´Oreal, Galderma, Ichthyol, Incyte, Kalvista, Celltrion, Pharvaris, and Stadapharma. Andreas Wollenberg has served as an advisor or paid speaker for, or participated in clinical trials (with honoraria paid to the institution) sponsored by: AbbVie, Aileens, Almirall, Amgen, Apogee, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Incyte, Janssen-Cilag, Kyowa Kirin, Leo Pharma, L’Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Nektar, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi-Aventis and UCB. Brian Calimlim, Ayman Grada, Wan-Ju Lee, Chao Li, and Alvaro Moreira are full-time employees of AbbVie and may hold AbbVie stock or stock options.

The original studies that collected the data analyzed within this manuscript were approved by the IRB, were conducted in accordance with the Declaration of Helsinki, and informed consent was obtained for participants.